Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA:688373)
5.06
-0.15 (-2.88%)
At close: Nov 13, 2026
SHA:688373 Revenue
Shanghai MicuRx Pharmaceutical had revenue of 40.90M CNY in the quarter ending September 30, 2026, with 10.50% growth. This brings the company's total for the last twelve months to 168.22M, up 23.06% year-over-year. In the year 2025, Shanghai MicuRx Pharmaceutical had annual revenue of 141.77M with 8.83% growth. That makes Shanghai MicuRx Pharmaceutical the 32,446th largest company in the world by revenue and 5,035th in China.
Revenue (ttm)
168.22M
Revenue Growth
+23.06%
P/S Ratio
19.74
Revenue / Employee
1.11M
Employees
151
Market Cap
3.32B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 141.77M | 11.50M | 8.83% |
| Dec 31, 2024 | 130.27M | 39.50M | 43.51% |
| Dec 31, 2023 | 90.78M | 42.57M | 88.31% |
| Dec 31, 2022 | 48.21M | 40.55M | 529.33% |
| Dec 31, 2021 | 7.66M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shenzhen Neptunus Bioengineering | 21.33B |
| Jinhe Biotechnology CO., LTD. | 2.94B |
| Huaren Pharmaceutical | 1.22B |
| ChengDu ShengNuo Biotec | 962.54M |
| PKU HealthCare Corp.,Ltd. | 903.60M |
| Harbin Medisan Pharmaceutical | 831.90M |
| Shandong Wohua Pharmaceutical | 781.18M |
| Newland Pharmaceutical | 733.72M |